The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.
about
Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleedingEmergency department visits for antibiotic-associated adverse eventsPrescribing warfarin appropriately to meet patient safety goals.Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational studyHigh-risk antimicrobial prescriptions among ambulatory patients on warfarin.Reversal of warfarin-induced hemorrhage in the emergency department.Macroscopic hematuria in patients on anticoagulation therapy.Factors influencing warfarin response in hospitalized patients.Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa.Interactions between warfarin and three commonly prescribed fluoroquinolones.Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series.What affects anticoagulation control in patients taking warfarin?Azithromycin in periodontal treatment: more than an antibiotic.Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.Warfarin monitoring in nursing homes assessed by case histories. Do recommendations and electronic alerts affect judgements?Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration.Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation.Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.Case Series Analysis of New Zealand Reports of Rapid Intense Potentiation of Warfarin by Roxithromycin.Microbiome facilitated pest resistance: potential problems and uses.Impact of a Guideline for the Management of Antimicrobial/Warfarin Interactions in the Inpatient Setting and Across Transition of Care.[Management and therapy of atrial fibrillation in geriatric patients].Common Drug Side Effects and Drug-Drug Interactions in Elderly Adults in Primary Care
P2860
Q24647605-03F98BB7-FD62-40A8-BD46-19B6047FADEBQ28290501-3048BAD7-06A4-4BC5-BB30-F1124CC5A2F1Q33932089-03C2235F-8086-4CAC-94E3-E9D501ADC37FQ33978811-6BD6F382-9087-42ED-8876-1DAC9475B42FQ34228198-25918E04-D9D9-4202-9142-1ED2273A0648Q35131841-322774DA-44EC-4672-9E0D-19696490A39DQ35608280-9C47C2EA-3E16-4AFC-A3E9-161A4DE72977Q36276807-C17A3C2A-77DD-46BA-B424-B9A41017757DQ36346124-D5C2E633-BC0D-4482-9293-4DF0EF8D839DQ37015862-4C1D317B-F53E-4B87-8107-150B2B9FDDF3Q37019758-56679CE4-72C9-4A88-93BD-DBC87D848720Q37138850-2FEF7C23-D2A9-4013-B59D-9D1ECC1DF995Q37199759-AF433CD7-9E5B-4DEE-8C35-D3A53D2E498FQ37272523-278AE542-BAAE-461C-8EC2-0222508B3D97Q37952308-6A7FE3B1-1E85-4FC0-89AD-3EB9211EA874Q39326279-E3EB8489-9ABA-470C-9387-EC82F35407B3Q41434261-2E833CC1-D4D1-4B50-AF5D-D54CFC3CA856Q41903969-3CD063EF-5637-4149-ADD0-075A2C0551F5Q43685010-0F6B8F11-D266-4D1F-9EB6-60248316454BQ44848854-6ABE28A2-6C1D-48BD-94AE-7809D635213DQ47657752-29F06491-4171-4186-9E1F-A117DF1647D2Q48124051-89A39407-0D1D-4C76-AE60-26FD082DD70FQ53597689-420C2797-A6CA-42C9-9C2A-4D418AF93D70Q54184682-FCCB6745-5C43-42B5-AB3E-28B0930065AAQ57256820-12B01BE4-2A95-42D4-8AF0-1227060BF934
P2860
The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@ast
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@en
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@nl
type
label
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@ast
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@en
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@nl
prefLabel
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@ast
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@en
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@nl
P2093
P2860
P1476
The risk of overanticoagulatio ...... s on stable warfarin regimens.
@en
P2093
Allan V Prochazka
Jeffrey J Glasheen
Randolph V Fugit
P2860
P2888
P304
P356
10.1007/S11606-005-0113-5
P577
2005-07-01T00:00:00Z
P5875
P6179
1019605884